Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Halozyme Therapeutics, with nine buy ratings, three holds and one sell. The average 12-month price target is $91.20, though several firms recently raised targets as high as $110.
• Halozyme reported strong quarterly results, posting EPS of $2.28 versus the $1.79 estimate and revenue of $481 million versus $402.28 million expected. Revenue increased 47.7% year over year, and fiscal 2026 EPS guidance is $8.65–$9.00.
• The stock opened at $111.56, near its 52-week high of $116.85, while insiders sold $8.7 million of shares over the past quarter; institutional investors own 97.79% of the company.

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $91.20.

Several research analysts recently commented on HALO shares. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Weiss Ratings raised shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, August 31st. TD Cowen lifted their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Citigroup reissued a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th.

Halozyme Therapeutics Stock Down 1.2%

Shares of Halozyme Therapeutics stock opened at $111.56 on Wednesday. The firm has a market cap of $12.66 billion, a PE ratio of 33.30, a P/E/G ratio of 0.43 and a beta of 0.88. The business's 50 day simple moving average is $101.77 and its 200 day simple moving average is $80.61. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $116.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business's revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts predict that Halozyme Therapeutics will post 8.25 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $82,336,727.20. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 82,545 shares of company stock valued at $8,744,180. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. MidFirst Bank bought a new stake in Halozyme Therapeutics during the second quarter worth $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics in the second quarter valued at $28,000. Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $30,000. Harbour Investments Inc. grew its position in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 372 shares during the period. Finally, Caitlin John LLC acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $44,000. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.